Therapeutic drug monitoring · 2025
Cyclosporin A Monitoring in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: A Comparison Between Siemens Viva-ProE System and LC-MS/MS.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lin Rongqi, Fan Xianghui, Li Xueyong, Lai Guixiang, Chen Ming, Huang Yingbin, Fu Qinghui, Lai Kaixian, Cheng Yu, Wu Xuemei, Qiu Hongqiang, Chen Yisheng
Аннотация
BACKGROUND: Allogeneic hematopoietic stem-cell transplantation is a critical treatment for blood-related diseases often complicated by graft-versus-host disease and managed using cyclosporin A (CsA). Therapeutic drug monitoring is essential due to the narrow therapeutic window of CsA.
METHODS: In this study, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of whole-blood CsA concentrations was developed and validated. CsA concentration in allogeneic hematopoietic stem-cell transplantation patients was measured using the newly established LC-MS/MS and the enzyme multiplied immunoassay technique-based Siemens viva-ProE system. The results from both methods were statistically analyzed across different concentration ranges to evaluate method agreement, correlation, and clinical implications.
RESULTS: The established LC-MS/MS method demonstrated excellent linearity (r 2 = 0.9983) within the CsA concentration range of 10-1000 ng/mL, with the validation parameters meeting the bioanalytical method validation criteria. Analysis of 161 samples revealed a strong correlation (r = 0.9908) between the methods; however, Siemens viva-ProE system overestimated CsA levels by an average of 8.7%, with a greater bias at higher concentrations. Correction through Deming regression significantly improved the agreement at therapeutically relevant thresholds.
CONCLUSIONS: The developed LC-MS/MS assay demonstrated acceptable performance in measuring CsA concentration in whole blood. The comparison between the 2 methods highlights the need for method specification in therapeutic drug monitoring and provides regression equations to enhance the monitoring accuracy in clinical practice.
METHODS: In this study, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of whole-blood CsA concentrations was developed and validated. CsA concentration in allogeneic hematopoietic stem-cell transplantation patients was measured using the newly established LC-MS/MS and the enzyme multiplied immunoassay technique-based Siemens viva-ProE system. The results from both methods were statistically analyzed across different concentration ranges to evaluate method agreement, correlation, and clinical implications.
RESULTS: The established LC-MS/MS method demonstrated excellent linearity (r 2 = 0.9983) within the CsA concentration range of 10-1000 ng/mL, with the validation parameters meeting the bioanalytical method validation criteria. Analysis of 161 samples revealed a strong correlation (r = 0.9908) between the methods; however, Siemens viva-ProE system overestimated CsA levels by an average of 8.7%, with a greater bias at higher concentrations. Correction through Deming regression significantly improved the agreement at therapeutically relevant thresholds.
CONCLUSIONS: The developed LC-MS/MS assay demonstrated acceptable performance in measuring CsA concentration in whole blood. The comparison between the 2 methods highlights the need for method specification in therapeutic drug monitoring and provides regression equations to enhance the monitoring accuracy in clinical practice.